Hepatitis B antigenaemia on Wuvulu Island.

A survey of the population of Wuvulu Island was undertaken to determine the prevalence of hepatitis B antigenaemia (HBsAg). Seventy-five percent of the population were tested, and 17.7% of those tested were positive for HBsAg. The percentage of positive sera increased with age but declined in the 5th decade of life. There was a marked difference in positivity between the two villages on the island (25.9% and 9.9%) which cannot be explained by several existing hypotheses for HBsAg transmission.

A randomized trial of ivermectin versus albendazole for the treatment of cutaneous larva migrans.

In an open study, we compared the efficacy of single doses of oral ivermectin (12 mg) and oral albendazole (400 mg) for the treatment of cutaneous larva migrans. Twenty-one patients were randomly assigned to receive ivermectin (n = 10) or albendazole (n = 11). All patients who received ivermectin responded and none relapsed (cure rate = 100%). All but one patient in the group receiving albendazole responded, but five relapsed after a mean of 11 days (cure rate = 46%; P = 0.017). No major adverse effects were observed. We conclude that a single 12-mg dose of ivermectin is more effective than a single 400-mg dose of albendazole for the treatment of cutaneous larva migrans.

Short- and long-term action of multiple doses of ivermectin on loiasis microfilaremia.

One hundred nine Gabonese patients infected with Loa loa microfilariae were treated with ivermectin (200 microg/kg of body weight) at the Parasitology, Mycology and Tropical Medicine Department (Faculte de Medecine et des Sciences de la Sante, Libreville, Gabon). Each was given one dose per month for six consecutive months. The peripheral blood microfilaria (mf) count before and after each dose showed an average decrease in the microfilaremia of 87.3% (short-term-single dose). An annual single-dose mass treatment with 200 microg/kg of ivermectin was sufficient to control the parasite in populations with low (< 400/ml) L. loa mf counts. One month after the sixth dose (short-term-multiple doses), the average microfilaremia rate had decreased by 99.2% compared with the initial infection (35 patients). Samples were taken from 28 patients one month after the first dose and one month after the sixth dose. The average mf count decreased by 96.4% after the first dose and by 99.6% after the sixth dose (average residual mf counts = 13.7 and 1.5 mf/ml, respectively). The mf count after the sixth dose was only 11.2% of the count after the first dose. The low mf count persisted for more than six months after the sixth treatment (long-term-multiple doses). Thus, mass treatment with multiple doses is more appropriate for areas where the blood mf count is very high. These results show that the number of the annual treatments used in mass chemotherapy with ivermectin can be adapted to each population to provide efficient protection.

Ivermectin in loiasis and concomitant O. volvulus and M. perstans infections.

Two clinical studies were carried out in Gabon, Africa to evaluate the efficacy, safety, and tolerability of ivermectin in the treatment of patients with Loa loa infection. In the first study, 35 patients received single oral doses of ivermectin, 5-200 mcg/kg body weight. Blood microfilariae levels did not decrease after a single oral 5, 10, 30, or 50 mcg/kg dose of ivermectin, but levels did decrease after doses of 100, 150, and 200 mcg/kg. The most efficacious dose was 200 mcg/kg; mean blood microfilariae levels decreased to 12% of mean pretreatment values by day 15 and remained decreased for 28 days. A second study evaluated the safety and efficacy of ivermectin in patients with multifilarial infections. All 17 patients had concomitant Loa loa and O. volvulus infection. M. perstans affected 5 of the patients. Sixteen patients also had infections due to intestinal nematodes. The patients each received single oral doses of 200 mcg/kg ivermectin. Ten days later, the mean Loa loa blood microfilariae level had decreased to 20% of the mean pretreatment level. O. volvulus dermal microfilariae densities were reduced to 2% of the pretreatment levels. A minimal increase in blood microfilaria levels was observed on day 28. In contrast, dermal microfilariae levels remained near zero for the duration of the study. Intestinal infection due to Ascaris was eradicated in all of the affected patients by day 23; efficacy against Trichuris and hookworm infections, however, was poor. All patients tolerated ivermectin well including those with multiple infections.

Reduced Loa loa microfilaria count ten to twelve months after a single dose of ivermectin.

The action of a single dose of ivermectin (200 micrograms/kg) on 71 Gabonese patients with Loa loa microfilariae in the peripheral blood, and living in areas highly endemic for loiasis, has been evaluated. Ten to 12 months after treatment, 43 patients (63%) had no circulating microfilaria and the geometric mean peripheral blood microfilaria count had decreased by 88.6% (P < 0.02). Thus, a single annual dose of ivermectin can markedly reduce loiasis transmission.

Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 cases.

Ivermectin is highly effective against animal intestinal nematodes and is used in the treatment of onchocerciasis in humans. A study was undertaken to compare the efficacy of the drug with that of albendazole in the treatment of uncomplicated strongyloidiasis. Sixty patients with confirmed Strongyloides stercoralis infection were enrolled in an open randomized study and given either albendazole, 400 mg/d for 3 d or ivermectin, 150-200 micrograms/kg in a single dose. Efficacy and tolerance were evaluated on days 7, 30 and 90. Each visit included a parasitological examination of 3 stool specimens, using saline and Kato smears and formalin-ether and Baermann concentrations. Fifty-three patients were eligible for evaluation. Parasitological cure was obtained in 24 of the 29 patients treated with ivermectin (83%) and in 9 of the 24 patients who were given albendazole (38%); ivermectin was significantly more effective than albendazole (P < 0.01). Clinical and biological adverse reactions were negligible in both treatment groups. The 20 patients who failed therapy were given a second treatment course with 150-200 micrograms/kg of ivermectin in a single dose or on 2 consecutive days. Sixteen patients were cured and the other 4 had only incomplete follow-up. Ivermectin therefore constitutes an acceptable therapeutic alternative for uncomplicated strongyloidiasis.

A double-blind comparison of the efficacy and safety of ivermectin and diethylcarbamazine in a placebo controlled study of Senegalese patients with onchocerciasis.

Ivermectin (MK-933) has been compared with diethylcarbamazine (DEC) and placebo in a double-blind study in 30 adult male Senegalese patients with Onchocerca volvulus infection. 10 patients were randomly assigned to each treatment group. Ivermectin was administered as a single oral dose of 12 mg and DEC as 50 mg daily for two days and 100 mg twice daily for the following six days, total 1.3 g in eight days. Skin O. volvulus microfilaria densities remained near pre-study values in the placebo patients, but decreased rapidly with both active drugs to mean values about 2% of pretreatment (Day 8) and then increased slowly, reaching in 12 months about 4% of pre-treatment (ivermectin) and 18% (DEC). This difference is statistically significant. Clinical adverse reactions were recorded in four ivermectin, ten DEC and three placebo patients. One ivermectin and six DEC patients received steroid treatment for relief of these reactions. Serious adverse ocular changes were not seen in any patients, possibly because of the steroid therapy in the DEC patients. Adult O. volvulus from onchocercal nodules one and six months after treatment showed no effect of either drug on viability. Intra-uterine developing forms of the microfilariae appeared normal in all three treatment groups at the one month examination but deformed and degenerated forms were evident at six months in the ivermectin group but not in the DEC and placebo patients. Ivermectin as a single oral dose appears to be a safer and more effective microfilaricidal drug in human onchocerciasis than DEC in the standard multi-dose regimen.

An entomological survey on the mosquitoes of Wuvulu Island, Papua-New Guinea.

An entomological survey in Wuvulu Island, Papua New Guinea, in August 1975 and 1976 shows the presence of six mosquito species: Aedes (S.) hebrideus, AE. (F.) notoscriptus, AE. (V.) lineatus, ? Ae. (L.) dasyorrhus, Culex pipiens fatigans and Armigeres breinli. The medical significance of these mosquitoes is discussed, with special reference to the problem of dengue virus transmission.

[Human onchocerciasis and "sowda" in the Republic of Yemen]. / Onchocercoses humaines et "sowda" en République du Yémen.

The geophysics of the north Yemen, associating a north-south directed mountainous fish bone (rising in more of 2,000 meters), to numerous rivers or "wadis" is convenient to the development of simulium shelters, main vectors for cutaneous filariasis to Onchocerca sp. Following several missions of bio-clinical and epidemiological evaluations in neighbouring villages of wadis, it has been possible to study different clinical aspects: one reminding the classical african onchocerciasis with generalized and diffused dermatitis, and, on an other hand, a hyperreactive dermatitis on one side of the body and associated with a collateral lymphatic ganglion. This disease is well known for local populations as "aswad" meaning "black" or "sowda". Clinically whatever the studied focus, coexists the two types of onchodermatitis (uni or bilateral). Yhe sowda patients are proportionally less numerous than those touched by the generalized type. Frequent eye lesions of the West African onchocerciasis are not found in sowda cases. In classical optical microscopy, microfilaria is morphologically indifferenciable between sowda and onchocerciasis clinical aspects. Skin snips were carried out on patients of both groups. Identification of microfilaria by molecular biology through the study of the DNA genome was done out of 5 skin snips. Microfilaria was kept dry between laminas and the DNA extracted from rehydrated microfilaria. DNA was intensified with specific primers of Onchocerca type (O150PCR). This phase was followed by hybridisation of amplification products by PCR to specific stains: OVS-2 for Onchocerca volvulus species, OCH for Onchocerca ochengi, PFS1 and PSS1-BT respectively for the forest strain and the savannah strain of Onchocerca volvulus as described previously. We can distinguish 2 kinds of answers based on the clinical origin of the snip-tests: the first one concern 3 patients with numerous dermal microfilariae but without any clinical sowda and corresponding to microfilaria O. volvulus type but different from the forest or savannah strains found in sub-Saharan Africa. The second one corresponds to 2 patients with less than 5 microfilaria in their snip-test. They show the typical clinical picture of sowda. They are identified as microfilaria type Onchocerca but they do not belong to species volvulus, or to species ochengi. It seems quite probable that the clinical picture of sowda be the result of developing onchocerciasis of animal origin and not identified as to day. The ivermectin, therapeutic of choice for African onchocerciasis in annual unique cure seems less effective in the coverage of sowda. In that case rehearsal of cures every 3 months would be necessary for mass campaigns to limit the transmission of this filariasis.

[Onchodermatitis (sowda) in patients in Yémen. Clinical and histologic course after treatment with ivermectin]. / Onchodermatite (Sowda) chez des patients du Yémen. Evolution clinique et histologique après traitement par ivermectine.

Sowda skin lesions are of medical and social importance in Yemen. Ivermectin (Mectizan) chose as a control strategy plan in onchocerciasis is active during 3 months for the less on clinical and histological data. After a short increase of itching and oedematous skin aspects clinical signs decrease. Some patients notice an itching rebound after 90 days. Histologically, localized ingratiates, presence of mononuclear cells and melenin loaded histiocytes and eosinophils decreased. The rythm cure has to be studied on a longer period but 3 to 6 months repetition between oral treatment with 200 micrograms/kg dose during two years could be effective.

[Anthihelminthic activity of pyrantel pamoate administered in mass treatment of an isolated population of the South Pacific]. / Activité anthelminthique du pamoate de pyrantel administré en traitement de masse dans une population isolée du Pacifique Sud

A stool examination survey on the Wuvulu island population in Papua-New Guinea let be shown off the high incidence of two helminthiasis, ascariasis and trichocephalosis (75-4 0/0 and 70 0/0 of the tested subjects) compared to the low incidence of ankylostomiasis (7 0/0). With pyrantel pamoate administered in one oral dose of 10 mg by kg of weight, results are excellent in ascariasis with 97-7 0/0 success. The efficiency is only partial in ankylostomiasis with that small dose. It is quite well tolerated and may be used in mass treatment and, taking into account the special characteristics of that small and far away island, an attempt to eradicate ascariasis through systematic reiterated treatments is being carried out.

[Results of an entomological survey of mosquitoes (diptera:Culicidae) in Hermit Islands and Wuvulu Island (Papua, New Guinea)]. / Résultats d'une enquête entomologique sur les moustiques (Diptères, Culicidae) dans les iles Hermites et sur l'île Wuvulu (Papouasie-Nouvelle-Guinée).

An entomological survey conducted on Wuvulu Island and Maron Island, Hermit group, Papua-New Guinea, in August 1975, 1976 and 1978, shows the presence of eight mosquito species: Anopheles (C.) farauti, Aedes (S.), hebrideus, A. (F.) notoscriptus, A. (V.) lineatus, A. (L.) dasyorrhus, Culex (C.) sitiens, C. (C.) pipiens fatigans and Armigeres breinli. The potential medical significance of these mosquitoes is discussed, with reference to malaria, dengue and filariasis.

A sero-epidemiologic survey on arbovirus in Wuvulu Island.

The authors present here the results of a serological survey on arbovirus infections, which was conducted on 116 out of 505 inhibitants of Wuvulu island, the westernmost island of the Bismarck archipelago, located 260 km north of Wewak, Papua-New Guinea. The islanders are divided in two communities of unequal size: the Wuvulian themselves, who are Micronesians, and the coconut workers who are Melanesians coming from the Sepik district. In addition to the presence of a group A virus, this survey shows a recent infection in the Melanesians by Dengue type 2 virus, probably during the 1971-72 epidemic. The virus did not reach Wuvulu island, as shown by negative results observed in the micronesian sera. A better knowledge of the potential dengue mosquito vectors would be useful in order to define the risk of an eventual introduction of the virus on the remote island.

[The efficacy and tolerance of ivermectin (Mectizan) prescribed for the patient with multiple filarial infections (Loa loa/Onchocerca and/or M. perstans)]. / Efficacité et tolérance de l'ivermectine (Mectizan) prescrit chez le sujet multifilarien (Loa loa/onchocercose et/ou M. perstans).

Administration of ivermectin (Mectizan) in Loa loa filariasis induces a significant decrease of microfilaria load within 3 to 15 days. The excellent tolerability of the drug in patients infested simultaneously by O. volvulus and Loa loa allows to use ivermectin in mass treatments in geographical areas where the same patients can be affected by several filariasis. There is almost no efficacy against Mansonella perstans. A second administration one month after the first one in Loa loa affected patients has not led to a complete disappearance of microfilaria; the tolerability has still been good. Efficacy on Ascaris lumbricoides appears to be excellent; further studies are necessary in the cases of trichuriasis, ancylostomiasis and strongyloidiasis.